Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab
Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab,...
Saved in:
Main Authors: | Shingo Nakayama, Mamoru Sasaki, Shojiroh Morinaga, Naoto Minematsu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2018/5863015 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review
by: Tomoo Kakimoto, et al.
Published: (2019-01-01) -
Asymptomatic Pulmonary Artery Intimal Sarcoma with Chest Wall Metastasis as an Initial Manifestation: An Autopsy Case
by: Tomoo Kakimoto, et al.
Published: (2018-01-01) -
Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
by: Daniel R. Gomez, et al.
Published: (2012-01-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)